WHO ICTRP trial
A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical…
ChiCTR-TRC-13003449 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-TRC-13003449 |
|---|---|
| Public title | A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomide in the treatment of Ankylosing Spondylitis |
| Scientific title | A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomide in the treatment of Ankylosing Spondylitis |
| Primary sponsor | The General Hospital of People's Liberation Army |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | II (Phase II study) |
| Countries | China |
| Conditions | Ankylosing Spondylitis |
| Interventions | Thalidomide 150mg:Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd, po., to the end;Thalidomide 100mg:Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks; 100mg/qd.po.to the end;Control group:Placebo po. |
| Registration date | Jun 7, 2013 |
| Target size | Thalidomide 150mg:80;Thalidomide 100mg:80;Control group:40 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: